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Abstract Despite high vaccination coverage, over the last
fifteen years there has been a worldwide resurgence of B.
pertussis infection. While classical pertussis in the prevac-
cine era was primarily a childhood disease, today with
widespread vaccination, there has been a shift in the
incidence of disease to adolescents and adults. Centers of
Disease Control and Prevention (CDC) data from 2004
reveal a nearly 19-fold increase in the number of cases in
individuals 10–19 years and a 16-fold increase in persons
over 20 years. Indeed adolescent and adults play a significant
role in the transmission of pertussis to neonates and infants
who are vulnerable to substantial morbidity and mortality
from pertussis infection. Several explanations have been
proposed to explain the increasing incidence of disease, with
waning immunity after natural infection or immunization
being widely cited as a significant factor. Improving molec-
ular biology diagnostic techniques, namely PCR assays, also
accounts for the increasing laboratory diagnosis of pertussis.
Expanding vaccination strategies including universal immu-
nization of adolescents, targeted immunization of adults, and
in particular, healthcare workers, childcare providers and
parents of newborns, will likely improve pertussis control.
With pertussis continuing to pose a serious threat to infants,
and greatly affecting adolescents and adults, there remains a
need to: (a) increase the awareness of physicians as to the
growing pertussis problem, (b) standardize diagnostic tech-
niques, and (c) implement various new vaccine strategies to
enhance its control.
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Abbreviations
ACIP Advisory Committee on Immunization
Practices
APERT Adult Pertussis Trial
CDC Centers of Disease Control and Prevention
Eupertstrain European research programme for improved
pertussis strain characterization and
surveillance
FHA Filamentous hemmaglutinin
GMT Geometric mean titer
GPI Global Pertussis Initiative
NIH National Institute of Health
PCR Polymerase chain reaction
PT Pertussis toxin
DTaP Diphtheria vaccine (normal dose), tetanus
vaccine (normal dose), acellular pertussis
vaccine (normal dose)
DtaP Diphtheria vaccine (normal dose), low dose
tetanus vaccine (booster dose), acellular
pertussis vaccine (normal dose)
Tdap Tetanus vaccine (normal dose), low dose
diphtheria vaccine (booster dose), low dose
pertussis acellular vaccine (booster dose)
Td Tetanus vaccine (normal dose), low dose
diphtheria vaccine (booster dose)
WHO World Health Organization
Introduction
Pertussis, an acute infectious illness of the respiratory tract
remains endemic in developed nations despite high vacci-
nation coverage [7, 8, 16]. While the early use of whole-cell
vaccine was highly effective in reducing the incidence of
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has been a resurgence of reported pertussis over the last 15
years [8, 16, 31]. Worldwide, there are an estimated 50
million cases occurring annually (90% of which are in devel-
oping countries), and there are as many as 400,0000 pertussis-
related deaths [16, 31]. It is general consensus, moreover,
that the reported incidence of pertussis is considerably lower
than its actual incidence [8, 31].
Though in the prevaccine era pertussis was regarded as a
childhood disease affecting primarily young children,
pertussis epidemiology in the postvaccine era is different
[8, 17]. Infants are the most vulnerable group with the
highest rates of complications and mortality, yet adolescents
and adults now comprise a significant percentage of cases
and a conduit of infection for the infants [8, 13, 17].
PCR, culture, and serology are the mainstay of the
laboratory diagnosis of pertussis, with various factors
affecting the sensitivity and specificity of each modality
[8, 24, 36]. However, in recent years, PCR has become an
increasingly more popular tool and has significantly con-
tributed to the increasing laboratory diagnosis of pertussis
[8, 27, 36].
Advances have also been made with regard to prevention
and disease control, with experts from 17 countries recently
establishing the Global Pertussis Initiative (GPI) with the
aim of analyzing the status of pertussis and enhancing
existing immunization strategies [8, 15].
Epidemiology of pertussis
Before the introduction of the whole-cell pertussis vaccine
in the1940s, there were approximately 200,000 cases
reported annually in the US [37]. Immunizations reduced
disease rates and in 1976 pertussis incidence reached a
nadir of 1,010 reported cases [13, 37]. However, since that
time, there has been a substantial increase in the number of
cases reported [8, 13, 31]. Indeed, over the past 15 years,
there has been a marked increase in the incidence of
pertussis with reported disease in the US reaching a rate of
8.9 per 100,000 in 2004 with nearly 19,000 provisional
reported cases [7, 17]. It is also well established that,
despite high vaccination coverage for primary immuniza-
tion in infants and children, pertussis continues to be a
global concern with increased incidence in many countries
including Argentina, Australia, Canada, Italy, Japan, the
Netherlands, Switzerland and the US [31]. It is also widely
noted that in recent years there is a general shift in the age
distribution of pertussis, with adults and adolescents an
underrecognized but significant source of infection for
neonates and infants [8, 13, 15–17]. Data from the EUVAC-
NET project, a network for the epidemiologic surveillance
and control of communicable diseases in the European
community, demonstrate that between 1998 and 2002, the
rate of disease incidence remained stable at a high rate
among children less than 1 year old. Nevertheless, these
data indicate that the incidence rate among adults doubled
in 5 years [4]. Similarly, Centers for Disease Control and
Prevention (CDC) surveillance data from 1990–2003
demonstrate that the reported incidence of pertussis among
adolescents has substantially increased with a nearly ten-
fold rise [17]. Moreover, when comparing pertussis disease
rates in 1990–1993, recent CDC data from 2004 reveal a
nearly 19-fold increase in the number of cases in persons
aged 10–19 years and a 16-fold increase in persons over
20 years [13].
Several factors have been proposed as underlying the
increasing incidence of pertussis disease including waning
immunity with subsequent atypical disease manifestations,
increasing awareness by public health personnel with
subsequent enhanced surveillance and improved laboratory
diagnostics [8, 17, 31].
Waning of both vaccine-induced immunity and infection-
acquired immunity is widely cited as an important reason
for recent epidemiologic trends [7, 8, 36, 37]. While the
assessment of the duration of immunity afforded after
either natural infection or vaccination is complex, individ-
uals are clearly susceptible to initial infection/reinfection
after vaccination or previous pertussis illness, respectively.
Studies vary in their estimation of protection against disease
with protective immunity after natural infection waning
7–20 years after illness, and duration of immunity after
vaccination waning at approximately 4–12 years in chil-
dren [36]. Yet, regardless of the precise interval, when
individuals do contract pertussis after the waning of their
immunity, their disease manifestations are frequently atyp-
ical [8, 17, 27]. As such, their illness is often underdiag-
nosed. Such underdiagnosis poses a potentially serious
public-health concern in that those untreated persons with
protracted cough continue to unknowingly transmit the
disease to others.
Finally, it has been proposed that the increased incidence
rates may also be a function of enhanced surveillance as
well as improved and more sensitive diagnostic lab
techniques (e.g., PCR), in that such techniques allow for
the diagnosis of cases that would probably have been
missed in the past [8, 17, 27, 35]. Nevertheless, it is
important to note, that the current estimates are likely to be,
if anything, an underrepresentation of the true incidence of
disease [8, 31]. First, the clinical diagnosis of pertussis is
complicated by underconsulting, particularly among ado-
lescents and adults [8]. Second, with prolonged cough often
being their only clinical feature, by the time these
adolescents and adults finally do seek medical attention, it
is often too late to culture or detect the organism by PCR,
thus potentially resulting in a missed diagnosis [8, 17, 31,
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sion, modification of disease by immunization, mixed
infection, inconsistent definition, and insensitive nonstan-
dardized, poorly performed, or lack of available laboratory
tests, further complicate physician diagnosis [8]. While the
classic or “typical” pertussis may be easily recognized, it is
seen less often since general immunization began. Instead,
atypical pertussis, usually characterized by the absence of
whoop and often a somewhat shorter duration of cough, is
more common than classical pertussis among adolescents
and adults [8, 17]. And finally, it should be noted that,
immunized young children that are PCR positive for
B pertussis can be asymptomatic [29, 31].
Regardless of whether an individual displays classical
pertussis signs and symptoms or a more protracted, atypical
cough, pertussis may not be suspected because of the
misconception among many physicians that pertussis is a
childhood disease [8, 17]. Co-occurrence of other infections
like Influenza A or B, adenovirus, and RSV may also
complicate the clinical diagnosis [8]. And, finally, even
when diagnosed, pertussis is often underreported [8].
Indeed, Sutter and Cochi report that in the US, only an
estimated 11.6% of pertussis cases were actually reported
[17, 30]. Thus multiple institutional, clinical, and laboratory
factors diminish the true assessment of pertussis incidence,
and the current data clearly are an underestimation of the
true burden of disease.
Laboratory diagnosis of pertussis
Because accurate diagnosis of pertussis cannot be made by
clinical signs and symptoms alone, there is a need for
improved laboratory diagnosis of pertussis [17]. While
several laboratory techniques exist for the identification of
B. pertussis, namely, culture, serology and PCR, overall,
several practical factors may adversely affect the sensitivity
of its laboratory diagnosis. Delayed specimen collection,
poor specimen collection techniques, specimen transport
problems, and lab media contamination are but a few of the
practical constraints often influencing the outcomes of the
laboratory diagnosis of pertussis. Moreover, previous
exposure to the organism, patient’s age, stage of disease,
previous antibiotic administration, and immunization are
other factors that may have a substantial impact on the
sensitivity of the tests. Finally, limited access to diagnostic
or laboratory methods, in both developed and developing
countries, undoubtedly affects B. pertussis laboratory
confirmation [8, 24].
Culture B. pertussis is a fastidious gram-negative cocoba-
cillus, and its isolation from nasopharyngeal secretions
remains the gold standard for diagnosis. Culture requires
collection of a posterior nasopharyngeal specimen with a
dacron or calcium alginate swab. To increase the yield of
positive cultures, specimens should be immediately plated
onto selective Regan Lowe agar or Bordet Gengou
medium, selective media that are seldom readily available
in physician's offices because of their cost and short shelf-
life [17, 24]. The main reasons for failure of bacterial
growth in culture, from correctly collected and transported
specimens, stem from bacterial and fungal contamination
and the lack of fresh media [24]. Generally, 7–10 days are
required to grow, isolate, and identify the organism, an
obvious limitation of the culture method.
The timing of obtaining specimens for culture is also of
paramount importance and greatly affects its yield. The
proportion of patients testing positive for pertussis by
culture is highest when the initial specimens are obtained
early in the course of illness, i.e., during the early catarrhal
phase of the illness when the organism is present in the
nasopharynx in sufficient quantity. However, adults and
adolescents often present late in the course of their illness,
thereby greatly reducing the likelihood of culturing the
organism [17, 24]. Studies also demonstrate that propor-
tions of positive cultures decline in patients who have been
previously immunized and undoubtedly in those in whom
antibiotics have been started. Thus, given the limited
“window of opportunity” for positive culture, it is important
to stress that a negative culture does not exclude pertussis
[16]. Finally, it is important to emphasize, that despite its
low yield, culture should be attempted, as the bacterial
isolates are needed for genotypic and phenotypic analysis.
PCR The use of PCR for the diagnosis of pertussis is
rapidly evolving as it provides a sensitive, rapid means for
laboratory diagnosis in circumstances in which the proba-
bility of a positive culture is low [8, 17, 32, 35]. Notably,
the CDC and World Health Organization (WHO) now
include a positive PCR in their lab definition of pertussis
[17]. While the sensitivity of PCR also decreases somewhat
with the duration of cough and among previously immu-
nized individuals, it is nevertheless a significantly more
robust tool for diagnosis for those in the later stages of the
disease or for those who have already received antibiotics
[17, 35]. Specifically, in their 2005 consensus paper, the
European Research Programme for Improved Pertussis
Strain Characterization and Surveillance (EUpertstrain)
state that the real-time PCR is more sensitive than culture
for the detection of B. pertussis, especially after the first
3–4 weeks of coughing and after antibiotic therapy has
been initiated [16, 27]. In a prospective study in which
nasopharyngeal samples were obtained simultaneously for
both PCR and culture, the identification of B. pertussis
infections was nearly four-fold higher with PCR [8, 28].
Finally, PCR is an invaluable tool for the diagnosis of
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low and serology is problematic in this age group [1, 17].
As with culture, important factors for the successful
application of PCR in the diagnosis of infection by
Bordetella species include proper sample collection and
preparation. For example, a Dacron swab with a fine
flexible wire shaft, and not calcium alginate, is the recom-
mended swab. After obtaining the nasopharyngeal sample,
the swab should be shaken vigorously in saline solution, the
swab discarded and the vial sealed for further processing
[24]. Appropriate primer selection, amplification conditions,
and controls are also essential for effective PCR testing.
Primers have been derived from four chromosomal regions
and common primers employed in PCR detection systems
include IS481, IS1001 PTp1, and PTp2 [8, 24]. Inherent
with the high sensitivity, false positive results are a well-
recognized problem associated with the PCR diagnosis
of pertussis and other respiratory illnesses. While at the
present time, PCR is not routinely available and its methods
need more standardization, optimization, and quality con-
trol, in the future, an internationally accepted standardized
kit might be available, which would facilitate the expanded
use of PCR for pertussis diagnosis [16, 35].
Serology Natural infection with B. pertussis is followed by
an increase in serum levels of IgA, IgM, and IgG antibodies
to specific pertussis antigen whereas the primary immuni-
zation of children induces mainly IgM and IgG antibodies.
During the past 15 years, ELISAs have constituted the
mainstay of serologic diagnosis using specific B. pertussis
protein as antigens, and the serologic diagnosis of pertussis
is suspected with increases in IgA or IgG antibody titers to
pertussis toxin (PT), filamentous hemmaglutinin (FHA),
pertactin, fimbriae or sonicated whole organisms in two
serum samples collected 2–4 weeks apart [24]. Notably,
these antibody responses to FHA are not specific to B.
pertussis, but also occur following other Bordetella species;
moreover, these antibodies may be cross-reacting epitopes to
other bacteria including H. influenzae and M. pneumoniae.
Thus, the greatest sensitivity and specificity for the serol-
ogical diagnosis of B. pertussis infection is by ELISA
measurement of IgG and IgA antibodies to PT demonstrat-
ing at least a two-fold rise in titer between acute- and
convalescent-phase sera [24].
Still, the main problem in the serologic diagnosis of B.
pertussis by ELISA is the frequent delay in obtaining the
acute-phase specimen. In individuals with re-infections,
there is a rapid increase in titer such that if a “delayed”
acute-phase sample is obtained, the titer is likely to have
already peaked, thereby hampering the detection of the
significant titer increase between the acute- and convales-
cent-phase serum samples [24]. Notably, for those individ-
uals not recently immunized, a single-serum sample ELISA
may circumvent the problem, as ill patients will have
significantly higher ELISA titers than the geometric mean
titers (GMT) of healthy controls [23–25]. With this in mind,
although a rise in PT IgA is more suggestive of a recent
antibody response, it is less consistent than a PT IgG rise;
hence, in adolescents and adults, a single high value of IgG
or IgA antibodies to PTsuggests pertussis infection [17, 24,
35]. Indeed, de Melker et al. demonstrated that an IgG
concentration to PT of at least 100 units/mL in a single
serum sample was diagnostic of either a recent or active
pertussis infection [10].
The serological diagnosis of pertussis among infants also
has notable limitations. Some culture-positive patients,
particularly infants younger than 3 months, do not develop
measurable antibodies, a finding that calls into question the
utility of even obtaining a serum specimen for serology in
young infants [8].
In summary, despite the shortcomings of serology, a
single-sample serology test can be a useful tool, particularly
among older patients presenting late in the course of their
illness when culture and PCR testing are negative.
Use of antibiotics in the treatment and prevention of
pertussis Antimicrobial agents administered early in the
course of disease, i.e., during the catarrhal stage, may
ameliorate the disease; although, after the cough is
established antibiotics do not have a discernable effect on
the course of the illness, but rather are recommended to
limit the spread of organisms to other individuals [9].
Erythromycin, clarithromycin or azithromycin are now
considered first-line agents for treatment (and prophylaxis)
of pertussis in individuals 6 months of age or older
(Table 1). The antibiotic choice for infants younger than
6 months of age, however, requires special attention. The
FDA has not yet approved azithromycin or clarithromycin
for use in infants younger than 6 months; however, the
2006 AAP endorsed Red Book lists azithromycin as the
preferred macrolide for this age group because of the risk of
idiopathic hypertrophic pyloric stenosis associated with
erythromycin [9]. Notably however, there was a recent
report of infantile hypertrophic pyloric stenosis among two
young infants treated with azithromycin for pertussis [26].
Postexposure prophylaxis The American Academy of
Pediatrics’ 2006 Red Book recommends that chemopro-
phylaxis be administered to all household contacts and
other close contacts, regardless of age and immunization
status. The rationale behind this recommendation is that
administration of chemoprophylaxis to asymptomatic con-
tacts within 21 days of onset of cough in the index patient
can limit secondary transmission [9]. Other countries like
the United Kingdom limit the use of prophylaxis for the
protection of only those with the greatest risk from pertussis,
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review of literature on the use of erythromycin in prevent-
ing secondary transmission of pertussis to close contacts
concluded that in countries where effective pertussis vac-
cinesareinuse,chemoprophyalxisshouldbelimitedtothose
most susceptible to the complications of pertussis (i.e.,
unimmunized or partially immunized infants) and to those
individuals who come in close contact with the latter [11,
12]. Regardless of the policy, the agents, dose, and duration
of prophylaxis are the same as for treatment of pertussis.
Prevention of pertussis: vaccination strategies
Pertussis vaccines licensed for use in infants, children, and
adults vary across countries. These vaccines differ both in
terms of their active ingredients and in terms of the other
diseases for which coverage is provided (e.g., polio,
diptheria). For example, Repevax (Sanofi Pasteur) contains
diptheria, tetanus, pertussis (acellular, component) as well
as inactivated polio, whereas ADACEL contains only tetanus
toxoid, reduced diphtheria toxoid, and acellular pertussis.
Vaccination strategies similarly vary from country to
country. Over the last several years, many potential immu-
nization strategies have been proposed to improve pertussis
control (Table 2). Universal immunization of adolescents
and adults, selective perinatal immunization of women who
recently gave birth, and close contacts of newborns, are but
a few of the strategies that were discussed by the Global
Pertussis Initiative (GPI), which first convened in 2001.
Specified immunization goals also included improvement
of current infant and toddler vaccination programs [15].
The second GPI convened in 2005 and reiterated several
intervention strategies to address the ongoing severe pertus-
sis disease among neonates and infants [16].
Immunization of adolescents As previously noted, the
incidence of pertussis among adolescents is increasing and
these individuals then serve as a reservoir of infection to
unvaccinated or incompletely vaccinated infants [13]. Two
Tdap vaccines (Boostrix and ADACEL) are licensed for
use in the US. Recently, the CDCs Advisory Committee on
Immunization Practices (ACIP) has recommended routine
Tdap for adolescents from 11–18 years [3, 13, 16]. Several
other countries including Canada, Austria, Australia,
France, and Germany have also introduced the universal
immunization of adolescents [16]. In Germany, for exam-
ple, the current immunization schedule recommends DTaP
at 2, 3, 4, and 11–14 months, and dTaP at 5–6 years and at
9–17 years [14]. For a complete overview of the pertussis
vaccination in other European countries please access the
EUVAC.NET website [14]. Future studies will be needed to
evaluate the duration of protection afforded and the
potential need for an adult booster.
Immunization of adults The Adult Pertussis Trial (APERT),
a study sponsored by the United States’ National Institute
of Health (NIH), has recently demonstrated the efficacy of
acellular pertussis vaccines in preventing pertussis disease
in adults (and adolescents). [16, 20, 21, 34]. To date, only
Table 1 Recommended antimicrobial therapy and postexposure prophylaxis for pertussis in infants, children, adolescents, and adults [9]
Age Recommended drugs Alternative
Azithromycin Erythromycin Clarithromycin TMP-SMX
<1 mo 10 mg/kg per day as a single dose for 5 days
a 40–50 mg/kg per
day in 4 divided
doses for
14 days
Not
recommended
Contraindicated at <2 mo of age
1–5 mo See above See above 15 mg/kg per day
in 2 divided
doses for 7 days
≥2 mo of age: TMP, 8 mg/kg
per day; SMX, 40 mg/kg per
day in 2 doses for 14 days
≥6 mo and
children
10 mg/kg as a single dose on day 1 (maximum
500 mg); then 5 mg/kg per day as a single dose on
days 2–5 (maximum 250 mg/day)
See above
(maximum 2
g/day)
See above
(maximum 1
g/day)
See above
Adolescents
and adults
500 mg as a single dose on day 1, then 250 mg as
a single dose on days 2–5
2 g/day in 4
divided doses
for 14 days
1 g/day in
2 divided doses
for 7 days
TMP, 300 mg/day; SMX,
1600 mg/day in 2 divided
doses for 14 days
Used with permission of the American Academy of Pediatrics. Red Book: 2006 Report of the Committee on Infectious Diseases Book, American
Academy of Pediatrics, 2006
TMP trimethoprim, SMX sulfamethoxazole
aPreferred macrolide for this age because of risk of idiopathic hypertrophic pyloric stenosis associated with erythromycin
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mended adult immunization schedule in the US (October
2006–September 2007) now recommends that Tdap replace
a single dose of Td for adults <65 years who have not
previously received a dose of Tdap (either in the primary
series, booster or for wound management) [6]. Given the
increased public awareness of adolescent and adult pertus-
sis, in conjunction with perhaps an increased awareness
about vaccines in general (e.g., HPV and influenza), the
general public may be more receptive to a universal adult
vaccination against pertussis [16]. The expected benefits of
such programs would be to build up herd immunity and
reduce disease. Alternatively, the selective vaccination of
only those adults at highest risk of transmitting B. pertussis
to vulnerable infants is likely to decrease both the incidence
and the impact of pertussis on young infants. Regardless of
the approach used, successful adult vaccination programs
must include education and public awareness.
Cocoon strategy The vaccination of household members,
including parents and siblings of newborn infants, has been
recently coined the cocoon strategy [16]. Recent studies
have demonstrated that parents are frequently the source of
pertussis infection to their infants [2, 13, 16, 19, 22]. While
implementation of this strategy is expected to lead to only
modest reductions in typical adult cases, there is a strong
indirect effect on infants and young children. In countries
where universal immunization of adults is not yet feasible,
many experts consider such targeted immunization as
“worthy of implementation” [16]. Presently, the cocoon
strategy is recommended in several European countries,
including Australia, France, Germany, and Austria [16].
Maternal vaccination Although there is efficient placental
transfer of pertussis antibodies, low maternal levels and
rapid decay in newborns render the infants vulnerable to
life-threatening pertussis [16, 18]. Maternal immunization
during pregnancy might afford some degree of protection to
mother and infant during a vulnerable period, and the use of
Tdap during pregnancy is currently under consideration.
Neonatal vaccination Given the resurgence of reported
pertussis in infant populations noted in multiple countries,
and the high morbidity and mortality in this age group,
newborn pertussis immunization is a potentially attractive
strategy [5, 16, 19]. It is still unclear, however, if such a
strategy will induce sufficient and timely immunity for this
targeted immunization. Future trials are needed to address
these concerns.
Conclusion
Despite the increasing awareness of B. pertussis, it continues
to affect millions of people worldwide. While classical
pertussis was once regarded as a “child’s disease”, today,
pertussis poses a serious threat to infants, and greatly affects
adolescents adults, now functioning as reservoirs of
infection. While advances in molecular biology have
undoubtedly increased the capacity to diagnose pertussis,
work is still needed to standardize laboratory techniques.
The increased awareness of the pertussis problem among
experts and the lay public will hopefully pave the way for
the implementation of various vaccine strategies to enhance
its control.
Table 2 Immunization strategies assessed by GPI participants
a (see [15], Table 1, pg. S70)
Strategy Primary objectives Secondary objectives
1. Universal adult immunization Reduce morbidity in adults Reduce transmission to young infants
Develop herd immunity Reduce morbidity in older children
2. Selective immunization of new mothers, family,
and close contacts of newborns
Reduce transmission to infants Reduce morbidity in adults,
particularly young adults
3. Selective immunization of health care workers Reduce transmission to patients Reduce morbidity in health care
workers
4. Selective immunization of child care workers Reduce transmission to infants Reduce morbidity in child care
workers
5. Universal adolescent immunization Reduce morbidity in adolescents and young
adults
Reduce transmission to infants
Develop herd immunity
6. Preschool booster at 4 years of age Reduce morbidity in 4- to 6-year olds Reduce transmission to infants
Develop herd immunity
7. Reinforce and/or improve the current infant
and toddler immunization strategy
Reduce morbidity and mortality in infants,
toddlers, and children
Reduce overall circulation of
pertussis
Used with permission from Lippincott Williams & Wilkins
aEntries represent the consensus of opinion of the GPI participants
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